Navigation Links
Peptimmune Initiates Phase Ib Study of PI-2301 in Multiple Sclerosis Patients and Presentation at BIO 2008
Date:6/17/2008

CAMBRIDGE, Mass., June 17 /PRNewswire/ -- Peptimmune, Inc. a privately held biotechnology company, announced that physicians have treated the first participant in a clinical trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of PI-2301 in subjects with Secondary Progressive Multiple Sclerosis (SP-MS). PI-2301 is a novel peptide copolymer for the treatment of multiple sclerosis and other autoimmune diseases.

The Phase Ib multiple-ascending dose, double-blind, placebo-controlled randomized study will involve up to fifty-three subjects with SP-MS who will receive the drug once weekly in four escalating-dose cohorts. Following establishment of safety at potentially therapeutic doses and proof of pharmacologic mechanism, the Company plans to initiate its Phase II study in multiple sclerosis patients in early 2009.

"While the primary goal of this study is to demonstrate safety of PI-2301 in multiple sclerosis patients, we believe that this clinical trial is one of the most comprehensive looks at the pharmacologic effects of any immunomodulator in patients suffering from autoimmune diseases," stated Thomas P. Mathers, President and CEO of Peptimmune. Mr. Mathers will be presenting an overview of the PI-2301 clinical program at the BIO 2008 Business Forum, Wednesday, June 18th, at 9:00 a.m. PDT at the San Diego Convention Center, Room 2.

PI-2301 is a second-generation peptide copolymer from a similar compound class as Copaxone(R) (Teva Pharmaceuticals). PI-2301 works through immune modulation by enhancing the regulatory response of the immune system and thereby controlling the pathogenic autoimmune response observed in some diseases. In a Phase I single ascending dose, double blind placebo controlled randomized study, all doses of PI-2301 were safe and well tolerated, and no serious adverse events were observed. Pharmacodynamic assays demonstrated evidence of immune exposure consistent with the pharmacologic mechan
'/>"/>

SOURCE Peptimmune, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Peptimmune Presents Early Clinical Data at European Neurological Society and Federation of Clinical Immunology Societies Meetings
2. Peptimmune Completes Phase I Study with a Novel Peptide Copolymer for the Treatment of Multiple Sclerosis
3. Peptimmune Initiates Phase I Study With a Novel Peptide Copolymer for the Treatment of Multiple Sclerosis
4. Transdel Initiates Ketotransdel(TM) Phase 3 Clinical Program for Pain
5. Medivation Initiates Second Pivotal Phase 3 Trial of Dimebon(TM) in Patients With Alzheimers Disease
6. TorreyPines Therapeutics Initiates Clinical Trial to Evaluate Analgesic Effect of Oral Prodrug of Tezampanel
7. Nuvelo Initiates Phase 1B Clinical Trial of Anticoagulant NU172
8. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
9. Wyeth Initiates INTORACT -- A New Clinical Trial to Examine TORISEL Plus Avastin for First-Line Treatment of Advanced Kidney Cancer
10. Human Genome Sciences Initiates First Clinical Trial of Lead IAP Inhibitor HGS1029 in Advanced Solid Tumors
11. Sunesis Pharmaceuticals Initiates Phase 2 Clinical Trial of Voreloxin (SNS-595) in Acute Myeloid Leukemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2014)... 2014 Companies that supply Durable Medical ... contact consumers directly about purchasing such supplies even ... The American Osteopathic Association,s House of Delegates voted ... companies that supply Durable Medical Equipment unless such ... physician and the patient. Typically ...
(Date:7/21/2014)... , July 21, 2014 ... Research titled, "Global biosimilars/follow-on-biologics market (types, applications and ... Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and ... biosimilars market would reach $35 billion by 2020 ... penetration with clearer regulatory pathways in developed markets ...
(Date:7/21/2014)... , July 21, 2014  PowerVision, Inc., ... fluid-based accommodating intraocular lens, today announced that ... and Law Chair of Ophthalmology, and Professor of ... the company,s Scientific Advisory Board. ... the American Academy of Ophthalmology Lifetime Achievement award, ...
Breaking Medicine Technology:American Osteopathic Association Calls for Eliminating Unsolicited Requests to Purchase Medical Equipment 2Biosimilars/Follow-on-Biologics Market is Expected to Reach $35 Billion, Globally, by 2020 2Biosimilars/Follow-on-Biologics Market is Expected to Reach $35 Billion, Globally, by 2020 3Biosimilars/Follow-on-Biologics Market is Expected to Reach $35 Billion, Globally, by 2020 4PowerVision Appoints Ophthalmology Thought Leader Douglas D. Koch, M.D. to its Scientific Advisory Board 2PowerVision Appoints Ophthalmology Thought Leader Douglas D. Koch, M.D. to its Scientific Advisory Board 3PowerVision Appoints Ophthalmology Thought Leader Douglas D. Koch, M.D. to its Scientific Advisory Board 4
... American Scientific Resources, Incorporated (OTCQB: ASFX) today announced ... containing results for the quarter ending March 31, ... review the entire 10-Q filing. (Logo: ... also like to direct investors to its corporate ...
... ANN ARBOR, Mich., May 24, 2011 ... long-term mechanical ventilation often require extensive additional care, ... A new study led by University ... chronic conditions who require long-term mechanical ventilation have ...
Cached Medicine Technology:American Scientific Resources, Inc. Announces Quarterly Results 2U-M Study: Children Dependent on Long-Term Mechanical Ventilation Require Longer, More Expensive Hospital Care 2U-M Study: Children Dependent on Long-Term Mechanical Ventilation Require Longer, More Expensive Hospital Care 3
(Date:7/22/2014)... (PRWEB) July 22, 2014 Industry-leading health ... announce the release of Specialty Pharmacy Trends and ... book that provides a comprehensive overview of the current ... includes management strategies and tactics for:, , ... cost and utilization concerns — including details of coinsurance ...
(Date:7/22/2014)... 2014 To help offset the typical ... Training Institute of Miami is reducing the cost ... model Brief Strategic Family Therapy™. To implement evidence-based ... variety of funding sources, but those opportunities seem to ... we want to help relieve somehow,” said the model ...
(Date:7/22/2014)... (PRWEB) July 22, 2014 Getting breast implants ... be completely optional or due to medical necessity. Either way, ... how to prepare for it, says Robert Kraft, MD, Plastic ... breast implant removal surgeries are performed each year in the ... But 70 percent of those procedures stem from three main ...
(Date:7/22/2014)... The hair transplant experts at WeGrowHair.com / ... laser therapy and robotic assisted hair transplantation to ... suffering from hair loss. Alongside their unique Multi-Unit ... Extraction (FUE) procedures via ARTAS – the world’s ... their doctors use advanced digital mapping to more ...
(Date:7/21/2014)... cancer cells could boost the effectiveness of chemotherapy to ... new study reports. , Scientists at The Institute of ... engineered version of the virus used to vaccinate against ... isolated limb perfusion chemotherapy given directly to blood ... alternative to amputation was more effective in rats ...
Breaking Medicine News(10 mins):Health News:Latest Edition of Annual Book Provides Comprehensive Overview of the Specialty Pharmacy Arena 2Health News:FTTIM Makes Brief Strategic Family Therapy Training a Little More Affordable 2Health News:FTTIM Makes Brief Strategic Family Therapy Training a Little More Affordable 3Health News:Is Breast Implant Removal Right for You? Plastic Surgeon Dr. Robert Kraft With Advanced Dermatology, PC Explains Breast Implant Removal and Offers Tips On Procedure 2Health News:Is Breast Implant Removal Right for You? Plastic Surgeon Dr. Robert Kraft With Advanced Dermatology, PC Explains Breast Implant Removal and Offers Tips On Procedure 3Health News:WeGrowHair.com/PAI Medical Group Introduces Robotic Assisted Laser Therapy to Treat Hair Loss 2Health News:Viral therapy could boost limb-saving cancer treatment 2Health News:Viral therapy could boost limb-saving cancer treatment 3
... sorafenib helps reverse disease resistance to anti-hormonal therapy ... drug sorafenib may help "re-sensitize" certain breast cancer ... Center researchers say. , Women with estrogen-receptor or ... cancers often take anti-hormonal medicines, such as aromatase ...
... hormone-receptor positive, metastatic breast cancer may take medications for ... when the tumor becomes resistant to anti-hormonal drugs, treatment ... presented today at the 2008 ASCO Breast Cancer Symposiummay ... treatment approach can "re-sensitize" the tumor, allowing anti-hormonal drugs ...
... York Fashion Week,s Annual Destination to Feature VelaShape. , ... ... http://www.americanlaser.com [American Laser Centers __title__ American Laser], the largest ... the U.S., announces sponsorship of the STYLE360 show during New York ...
... samples provided to physicians by pharmaceutical companies could actually ... according to a study done by researchers at Wake ... retrospective study looked at the prescribing habits of more ... in the months immediately before and after the closing ...
... 3, 2008In a case-control study, the presence of measles ... autism and GI disturbances than in children with only ... were unrelated to MMR vaccine timing. Study findings ... Science on September 4 ( http://dx.plos.org/10.1371/journal.pone.0003140 ). , ...
... Experts develop sequence of instructions they say could help doctors ... safety experts say that almost all kids who are allergic ... set of standard precautions. , Reporting in the September ... by the Johns Hopkins Children,s Center put forth a step-by-step ...
Cached Medicine News:Health News:Drug Re-Sensitizes Breast Tumors to Treatment 2Health News:1 step back ... 2 steps forward 2Health News:American Laser Centers Sponsors STYLE360 to Share the Skinny on Body Shaping 2Health News:Free drug samples may end up costing uninsured more 2Health News:Free drug samples may end up costing uninsured more 3Health News:Study firmly shows no connection between measles, mumps, rubella (MMR) vaccine and autism 2Health News:Study firmly shows no connection between measles, mumps, rubella (MMR) vaccine and autism 3Health News:Even Kids With Known Allergies Can Be Safely Vaccinated 2
An intermediate set providing a greater range of telescopes than the starter set....
Significantly more compact and tidier in overall looks yet retain many of the excellent features of the more comprehensive Haag type systems., ,Filters include Cobalt blue; green (red free); neut...
... up to 20 tilting ... in the vertical, horizontal ... the option to offset ... transillumination., ,Filters include Cobalt ...
With a high lens and filter range this ophthalmoscope is ideal for the Primary Care Specialist...
Medicine Products: